HUTCHMED (China) Limited (HCM)
USD 14.89
(8.53%)
USD 14.89
(8.53%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 453.55 Million USD | 293.35% |
| 2022 | 115.3 Million USD | 17.79% |
| 2021 | 97.89 Million USD | 148.1% |
| 2020 | 39.45 Million USD | -11.8% |
| 2019 | 44.73 Million USD | -36.24% |
| 2018 | 70.16 Million USD | 7.31% |
| 2017 | 65.38 Million USD | 9.42% |
| 2016 | 59.75 Million USD | -11.38% |
| 2015 | 67.42 Million USD | 241.16% |
| 2014 | 19.76 Million USD | -16.83% |
| 2013 | 23.76 Million USD | -75.25% |
| 2012 | 95.99 Million USD | 3.48% |
| 2011 | 92.76 Million USD | 16.15% |
| 2010 | 79.86 Million USD | 20.26% |
| 2009 | 66.41 Million USD | 30.62% |
| 2008 | 50.84 Million USD | 35.75% |
| 2007 | 37.45 Million USD | 28.65% |
| 2006 | 29.11 Million USD | 25.24% |
| 2005 | 23.24 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 62.77 Million USD | 542.59% |
| 2024 Q2 | 62.77 Million USD | 0.0% |
| 2023 Q2 | 162.27 Million USD | 0.0% |
| 2023 Q4 | -14.18 Million USD | 0.0% |
| 2023 FY | 453.55 Million USD | 293.35% |
| 2023 Q1 | 162.27 Million USD | 309.96% |
| 2023 Q3 | -14.18 Million USD | -108.74% |
| 2022 FY | 115.3 Million USD | 17.79% |
| 2022 Q4 | -77.28 Million USD | 0.0% |
| 2022 Q3 | -77.28 Million USD | -219.4% |
| 2022 Q2 | 64.72 Million USD | 210.64% |
| 2022 Q1 | -58.5 Million USD | -817.34% |
| 2021 Q4 | 8.15 Million USD | 114.53% |
| 2021 FY | 97.89 Million USD | 148.1% |
| 2021 Q3 | -56.12 Million USD | -420.78% |
| 2021 Q1 | 16.61 Million USD | 139.31% |
| 2021 Q2 | 17.49 Million USD | 5.3% |
| 2020 Q4 | -42.26 Million USD | 0.0% |
| 2020 FY | 39.45 Million USD | -11.8% |
| 2020 Q2 | 12.91 Million USD | 25.61% |
| 2020 Q1 | 10.28 Million USD | 116.97% |
| 2020 Q3 | -42.26 Million USD | -427.34% |
| 2019 Q1 | 11.21 Million USD | -72.87% |
| 2019 Q2 | 12.39 Million USD | 10.55% |
| 2019 FY | 44.73 Million USD | -36.24% |
| 2019 Q3 | -20.32 Million USD | -263.95% |
| 2019 Q4 | -60.57 Million USD | -198.07% |
| 2018 Q3 | -3.1 Million USD | -120.66% |
| 2018 Q2 | 15.03 Million USD | -1.64% |
| 2018 Q1 | 15.28 Million USD | -44.84% |
| 2018 FY | 70.16 Million USD | 7.31% |
| 2018 Q4 | 41.32 Million USD | 1430.94% |
| 2017 FY | 65.38 Million USD | 9.42% |
| 2017 Q3 | -7.88 Million USD | -121.2% |
| 2017 Q4 | 27.7 Million USD | 451.33% |
| 2017 Q1 | 2.81 Million USD | 156.5% |
| 2017 Q2 | 37.19 Million USD | 1221.15% |
| 2016 Q1 | 1.42 Million USD | -94.27% |
| 2016 FY | 59.75 Million USD | -11.38% |
| 2016 Q2 | 1.42 Million USD | 0.0% |
| 2016 Q4 | -4.98 Million USD | 0.0% |
| 2016 Q3 | -4.98 Million USD | -450.05% |
| 2015 Q3 | 34.28 Million USD | 507.66% |
| 2015 FY | 67.42 Million USD | 241.16% |
| 2015 Q4 | 24.84 Million USD | -27.53% |
| 2015 Q2 | 5.64 Million USD | 0.0% |
| 2015 Q1 | 5.64 Million USD | 445.05% |
| 2014 FY | 19.76 Million USD | -16.83% |
| 2014 Q4 | -1.63 Million USD | -113.2% |
| 2014 Q2 | 4.5 Million USD | 0.0% |
| 2014 Q1 | 4.5 Million USD | 132.65% |
| 2014 Q3 | 12.39 Million USD | 175.06% |
| 2013 Q3 | 7.34 Million USD | 61.87% |
| 2013 Q1 | 4.53 Million USD | 81.05% |
| 2013 Q2 | 4.53 Million USD | 0.0% |
| 2013 FY | 23.76 Million USD | -75.25% |
| 2013 Q4 | -13.79 Million USD | -287.85% |
| 2012 FY | 95.99 Million USD | 3.48% |
| 2012 Q3 | 2.5 Million USD | 0.0% |
| 2012 Q4 | 2.5 Million USD | 0.0% |
| 2011 FY | 92.76 Million USD | 16.15% |
| 2010 FY | 79.86 Million USD | 20.26% |
| 2009 FY | 66.41 Million USD | 30.62% |
| 2008 FY | 50.84 Million USD | 35.75% |
| 2007 FY | 37.45 Million USD | 28.65% |
| 2006 FY | 29.11 Million USD | 25.24% |
| 2005 FY | 23.24 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | -39.054% |
| Embecta Corp. | 749.9 Million USD | 39.518% |
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | -48.558% |
| Dynavax Technologies Corporation | 182.11 Million USD | -149.044% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -520.734% |
| Pacira BioSciences, Inc. | 490.3 Million USD | 7.497% |
| PainReform Ltd. | -15 Thousand USD | 3023780.0% |
| Aquestive Therapeutics, Inc. | 29.75 Million USD | -1424.442% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -5338.814% |
| SCYNEXIS, Inc. | 124.51 Million USD | -264.249% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -81772.878% |
| Cosmos Health Inc. | 4.34 Million USD | -10327.516% |
| Journey Medical Corporation | 52.52 Million USD | -763.563% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -5338.814% |
| Safety Shot Inc | -74.45 Thousand USD | 609246.219% |
| Alpha Teknova, Inc. | 10.29 Million USD | -4305.128% |
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | -5.324% |
| Bright Green Corporation | -237.01 Thousand USD | 191459.233% |
| Procaps Group, S.A. | 239.56 Million USD | -89.32% |
| Theratechnologies Inc. | 62.12 Million USD | -630.017% |
| Harrow Health, Inc. | 90.55 Million USD | -400.869% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | -9458.525% |
| Biofrontera Inc. | 16.62 Million USD | -2627.804% |
| DURECT Corporation | 6.83 Million USD | -6539.614% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 13.402% |
| Cronos Group Inc. | 6.99 Million USD | -6387.752% |
| OptiNose, Inc. | 62.35 Million USD | -627.382% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | -2.809% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 149787.129% |
| RedHill Biopharma Ltd. | 3.05 Million USD | -14750.239% |
| Organogenesis Holdings Inc. | 309.79 Million USD | -46.406% |
| Guardion Health Sciences, Inc. | 5.39 Million USD | -8307.648% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | -1254.457% |
| Radius Health, Inc. | 307.71 Million USD | -47.395% |
| Universe Pharmaceuticals INC | 10.07 Million USD | -4400.47% |
| ProPhase Labs, Inc. | 16.23 Million USD | -2692.98% |
| Phibro Animal Health Corporation | 312.48 Million USD | -45.143% |
| Procaps Group S.A. | 239.56 Million USD | -89.32% |
| Alvotech | -69.42 Million USD | 753.326% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -34735.023% |
| Viatris Inc. | 6.43 Billion USD | 92.956% |
| Rockwell Medical, Inc. | 8.7 Million USD | -5110.846% |
| Aytu BioPharma, Inc. | 54.58 Million USD | -730.894% |
| SIGA Technologies, Inc. | 122.09 Million USD | -271.483% |
| Tilray Brands, Inc. | 223.35 Million USD | -103.067% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | -983.756% |
| Shineco, Inc. | 882.16 Thousand USD | -51313.336% |
| PetIQ, Inc. | 252.74 Million USD | -79.454% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 60931.451% |
| Incannex Healthcare Limited | 12 Thousand USD | -3779500.0% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 75.449% |
| Alimera Sciences, Inc. | 61.17 Million USD | -641.462% |
| Silver Spike Investment Corp. | 8.1 Million USD | -5497.611% |
| Assertio Holdings, Inc. | 125.04 Million USD | -262.699% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 6659210.263% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | -10721.613% |
| Clever Leaves Holdings Inc. | 6.55 Million USD | -6818.121% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 18918.211% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | -1572.574% |
| Hempacco Co., Inc. | -1.21 Million USD | 37403.807% |
| Talphera, Inc. | -4.89 Million USD | 9365.618% |
| Alvotech | -69.42 Million USD | 753.326% |
| Eagle Pharmaceuticals, Inc. | 221.67 Million USD | -104.603% |
| Lantheus Holdings, Inc. | 709.54 Million USD | 36.078% |
| Currenc Group, Inc. | 17.35 Million USD | -2513.183% |
| Kamada Ltd. | 52.59 Million USD | -762.385% |
| Indivior PLC | 907 Million USD | 49.994% |
| Evoke Pharma, Inc. | 4.97 Million USD | -9009.755% |
| Flora Growth Corp. | 17.73 Million USD | -2456.951% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 18918.211% |
| Evolus, Inc. | 140.52 Million USD | -222.753% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | -31.859% |
| Akanda Corp. | 111.44 Thousand USD | -406859.237% |